Share on StockTwits

Amicus Therapeutics (NASDAQ:FOLD) saw unusually large options trading on Wednesday. Stock investors bought 16,037 call options on the company, Analyst Ratings Network.com reports. This represents an increase of 473% compared to the typical volume of 2,800 call options.

A number of analysts have recently weighed in on FOLD shares. Analysts at Cowen and Company raised their price target on shares of Amicus Therapeutics to $14.00 in a research note on Wednesday. Separately, analysts at Janney Montgomery Scott upgraded shares of Amicus Therapeutics from a “neutral” rating to a “buy” rating in a research note on Tuesday, July 1st. They now have a $5.00 price target on the stock, up previously from $2.50. Finally, analysts at Leerink Swann upgraded shares of Amicus Therapeutics from a “market perform” rating to an “outperform” rating in a research note on Tuesday, July 1st. They now have a $6.00 price target on the stock, up previously from $2.50.

Shares of Amicus Therapeutics (NASDAQ:FOLD) traded up 20.35% on Wednesday, hitting $5.50. The stock had a trading volume of 33,691,964 shares. Amicus Therapeutics has a 1-year low of $1.77 and a 1-year high of $4.74. The stock has a 50-day moving average of $4.1 and a 200-day moving average of $2.81. The company’s market cap is $432.9 million.

Amicus Therapeutics (NASDAQ:FOLD) last announced its earnings results on Thursday, August 7th. The company reported ($0.31) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.23) by $0.08. Analysts expect that Amicus Therapeutics will post $-0.94 EPS for the current fiscal year.

Amicus Therapeutics, Inc (NASDAQ:FOLD) is a United States-based biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule drugs known as pharmacological chaperones for treating a range of diseases, including lysosomal storage diseases and diseases of neurodegeneration.

Receive News & Ratings for Amicus Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amicus Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.